Leerink cuts CVS Health stock target from USD 119.00 to USD 112.00

Published on 10/13/2026 at 11:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Diluted earnings per share reached USD 2.31 from USD 0.80 year over year. CVS Health stock costs EUR 78.77 on October 13, 2026, 1.22 percent above EUR 77.82.

Leerink Partners cut its CVS Health price target from USD 119.00 to USD 112.00 while retaining an Outperform rating.
Second-quarter diluted earnings per share reached USD 2.31, versus USD 0.80 a year earlier.
CVS Health stock was at EUR 78.77 at Lang & Schwarz on October 13, 2026, 1.22 percent above the Xetra close of EUR 77.82.
The next ex-dividend date is October 22, 2026, and second-quarter results are scheduled for November 4, 2026.

Bauhaus-Stil-Poster mit geometrischen Primärfarben und HEALTHCARE-Schriftzug im Modernismus-Design — CVS Health Corp. Bauhaus-Poster zeigt HEALTHCARE-Schriftzug mit kräftigen geometrischen Primärfarben, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (US1266501006) was trading at EUR 78.77 at Lang & Schwarz on October 13, 2026 at 11:46 a.m. CEST, 1.22 percent above the Xetra close of October 12, 2026 at EUR 77.82. The latest analyst action came from Leerink Partners, which cut its CVS Health price target from USD 119.00 to USD 112.00 while retaining an Outperform rating in a note dated October 12, 2026, according to MarketBeat.

Target cut meets stronger earnings

CVS Health reported diluted earnings per share of USD 2.31 in the second quarter of 2026, up from USD 0.80 in the year-earlier quarter. Revenue reached USD 106.10 billion in the same period, compared with USD 98.94 billion a year earlier, a 7.24 percent increase, according to finanzen.ch.

The standardized financial data show USD 2.979 billion in net income attributable to common shareholders and USD 6.345 billion in operating cash flow for the second quarter of 2026. Cash and cash equivalents stood at USD 11.329 billion on June 30, 2026.

What does the target cut change?

The lower USD 112.00 target contrasts with the latest operating improvement rather than erasing it. MarketBeat reported 20 Buy ratings and three Holds, with a consensus target of USD 107.80, while CVS maintained fiscal 2026 adjusted earnings guidance of USD 7.90 to USD 8.10.

The counterweight is execution risk. Zacks said second-quarter adjusted operating income in Pharmacy and Consumer Wellness rose 10.20 percent year over year, while same-store prescription volume increased 7.00 percent. The same analysis identified 340B pressure and declining Caremark membership as risks for near-term results.

Three dates frame the story

On August 5, 2026, CVS Health reported second-quarter diluted earnings per share of USD 2.31 and revenue of USD 106.10 billion. On October 1, 2026, McKesson announced an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, as reported by FinanzNachrichten. On October 12, 2026, Leerink Partners cut its target from USD 119.00 to USD 112.00.

Upcoming dates and stock context

The next ex-dividend date is October 22, 2026, with a quarterly dividend of USD 0.665 per share, according to MarketBeat. CVS Health's next quarterly results are scheduled for November 4, 2026, according to finanzen.ch.

At EUR 78.77, the Lang & Schwarz quote was 1.22 percent above the EUR 77.82 Xetra close on October 12, 2026. The primary-exchange reference range was USD 69.51 to USD 110.68 over 52 weeks, and market capitalization was USD 111.95 billion as of October 12, 2026. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.